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Abstract: Meningioma accounts for more than 30% of all 
intracranial tumours. It affects mainly the elderly above 
the age of 60, at a female:male ratio of 3:2. The progno-
sis is variable: it is usually favourable with no progres-
sion in tumour grade and no recurrence in WHO grade 
1 tumours. However, a minority of tumours represent 
atypical (grade 2) or anaplastic (grade 3) meningiomas; 
this heterogeneity is also reflected in histopathological 
appearances. Irrespective of the grade, the size of the 
tumour and the localisation may have severe, sometimes 
lethal consequences. Following neurosurgical interven-
tions to remove the tumour, recurrence and progression 
in WHO grade may occur. Our knowledge on predisposing 
histomorphological and molecular factors of recurrence is 
rather limited. These can be classified as I) demographic 
II) environmental, III) genetic and epigenetic IV) imaging, 
V) neuropathological, and VI) neurosurgical. In view of 
the complex background of tumour recurrence, the rec-
ognition of often subtle signs of increased risk of recur-
rence requires close collaboration of experts from several 
medical specialties. This multidisciplinary approach 
results in better therapy and fewer complications related 
to tumour recurrence.
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1  Introduction
Meningioma is one of the most frequent intracranial 
tumours. The prevalence peaks between the age of 60 and 
70 years, at a female:male ratio of 3:2. Nevertheless, the 
tumour may also occur in children. The most frequent 
localisations are parasagittal, lateral convexity, the wings 
of sphenoid bone, anterior fossa close to the olfactory 
nerve, the sellar region, and the posterior fossa in the 
vicinity of foramen magnum, respectively [1]. Most menin-
giomas are histologically benign. The WHO classification 
distinguishes three histological grades (1-2-3) and 15 sub-
types [2]. Although meningiomas are usually histologically 
benign, space occupying lesions within the close skull 
can never be considered absolutely risk free:  the increase 
of the intracranial pressure may lead to life-threatening 
complications. Because recurrence and progression are 
well known and not infrequent characteristics of menin-
giomas, a thorough analysis and better understanding 
of contributory factors are of crucial importance. In the 
current literature review, we assess the factors predic-
tive of tumour recurrence with focus on clinical conse-
quences, histological alterations, and risk factors related 
to the tumour treatment itself. Independent risk factors, 
such as sex and age, have also been analysed. Special 
emphasis has been devoted to predictive signs detectable 
by imaging techniques. The predictive values of immuno-
histochemical and other molecular markers in relation 
histological grade is increasingly recognised and there-
fore reviewed. Finally, the extent of surgical resection 
reflected by the Simpson grade appears to be very closely 
associated with the risk of recurrence. In summary, in this 
review we assess predictive factors derived from several 
neuro-specialties because their combined assessment can 
help to reach the best clinical decision on patient care 
(Figure 1).
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2  Predisposing factors of 
meningioma recurrence
2.1  Demographic factors 
The role of age and sex has been studied in relation to risk 
of recurrence. However, there has been no significant cor-
relation shown between these two factors [3-6].
2.2  Environmental factors
An important environmental and/or iatrogenic factor 
is the effect of ionising radiation on the head and neck 
region. The increased incidence of meningiomas among 
survivals of the Hiroshima nuclear disaster at the end of 
the Second World War also supports this notion. However, 
most cases of radiation-induced meningiomas are iatro-
genic and related to the diagnostic irradiation in dental 
practice. Therapeutic irradiation (radiotherapy) appears 
highly relevant, and there is growing body of evidence 
to support this [7-8]. Interestingly, traumatic head injury 
also increases the risk of meningioma 1 or 2 decades after 
the trauma in a dose-dependent manner and, apparently, 
unrelated to the severity of injury [9]. The female predom-
inance of meningioma raises the possibility of hormonal 
effects in its pathogenesis, although large scale epidemi-
ological studies have not provided unequivocal evidence 
to prove hormonal factors in pathogenesis, etiology and 
pathomechanism [10]. Nevertheless, it is well known 
that during pregnancy a meningioma may undergo rapid 
growth, which could have a lethal outcome [11]. In breast 
cancer sufferers there is also modest increase in incidence 
[12]. Long-term exogenous hormone replacement therapy 
has also been implicated in tumorigenesis [13]. Hu et al., 
in a comprehensive analysis, examined the role of various 
environmental factors in the Chinese population [14]. The 
results reveal that smoking significantly increases the 
incidence of meningioma in women. Similarly, lead, tin, 
cadmium as occupational hazards also increase meningi-
oma incidence in exposed workers. In contrast, a diet rich 
in fruits and vegetables decreases the chance of having 
a meningioma [14]. Although alcohol consumption has 
been implicated as a risk factor for meningioma, there are 
no convincing evidence to support this hypothesis [15]. 
With the advent of novel telecommunication techniques, 
in particular mobile phones, the question has emerged 
whether there is an association between meningioma 
development and use of cell phones. The Interphone 
company conducted a study that concluded there was 
no such association [16]. Nevertheless, we have to take 
into account that there are not many research reports on 
this field and that the follow-up period is relatively short 
because mobile phones have become widely used only in 
the past 20 years or so. 
2.3  Genetic and epigenetic aspects
Meningioma is also a component of numerous familiar 
tumour syndromes. It is most frequent in neurofibroma-
tosis type 2 (NF2) and can also occur in other congenital 
and familial diseases: multiple endocrine neoplasia type 1 
(MEN1), Gorlin-, Cowden-, Gardner-, Turcot-, von Hippel–
Lindau-(VHL), and Li–Fraumeni syndrome [17]. The NF2 
gene is located on the long arm of chromosome 22, coding 
tumour suppressor protein merlin. In sporadic cases (i.e., 
in meningiomas unrelated to tumour syndromes) a muta-
tion is found in 60% of cases. The frequency and type of 
mutation in various meningioma grades is roughly iden-
tical [18]. A novel avenue to an understanding of menin-
gioma pathogenesis is research into epigenetic mecha-
nisms. One of the first discovered epigenetic changes in 
tumours is aberrant DNA methylation. Although NF2 is 
relatively frequently mutated in meningioma, epigen-
etic alteration of NF2 is rare. In contrast, TIMP3, TP73, 
and RASSF1A promoters and HOXA7, HOXA9, HOXA10 
homebox genes are often hypermethylated in meningio-
mas. Another epigenetic change, histone modification, 
has no proven involvement in meningioma pathogenesis. 
The third major epigenetic factor, micro RNAs (miRNAs), 
are important in regulating post-translational silencing. 
Figure 1: Possible factors in meningioma recurrence
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miR-190a  is increased, whereas miR-29c-3p and miR-
219-5p are decreased in a subset of meningiomas; these 
tumours involve a higher risk of recurrence [19].
2.4  Imaging 
In tumour diagnostics and follow-up, imaging is crucial. 
The characteristic dural tail detectable on CT and MR 
images, peritumoral oedema, and calcification are all 
important features [1]. Significant correlation has been 
found between tumour size (>50mm), shape (mushroom), 
localisation (base of skull), presence of brain invasion, and 
the severity of peritumoral oedema [3, 20-23]. The latter 
is important in recurrence because oedema increases the 
chance of brain invasion by the tumour, which is a key 
factor in recurrence [24]. The large size, basal localisation, 
and malignant histological features are associated with 
increased severity of peritumoral edema [25].
2.5  Neuropathological characteristics 
2.5.1  Histological grade
The clinical behaviour and risk of recurrence have a very 
close association with the histological grade of the tumour. 
The histological grade and the extent of resection appear 
to be the two most important predictive factors of recur-
rence. According to the WHO classification, meningiomas 
are grouped in three grades (grade I, II, III). According to 
the typical morphological appearances and the mitotic 
index (assessed by the number of mitosis per 10 high 
power microscopic fields (HPF), there are 15 histological 
subtypes [2]. WHO grade I has 9, whereas both WHO II and 
WHO grade III have 3 subtypes (Table 1). Clear cell menin-
gioma is grade II if intracranial and grade I when it occurs 
in the vertebral canal.
In WHO grade II, atypical meningioma, a minimum 
of three of the following histomorphological features 
are detectable: increased cellularity; small cells with an 
increased nucleus/cytoplasm ratio; prominent nucleoli, 
‘patternless’ or sheet-like growth; focal small, geographic 
necrosis; 4 or more mitosis/10 HPF. In anaplastic (WHO 
grade III) meningioma there are obvious malignant cyto-
logical features, such as undifferentiated growth, which 
makes them similar to carcinoma, melanoma, or sarcoma 
(regarding cytological atypia). In anaplastic meningioma 
there are 20 or more mitoses/10 HPF.
Several studies have proven the close association 
between histological grade and risk of recurrence. In 
higher grade tumours (i.e., grades II, and III) the increased 
cellularity, higher mitotic rate, and presence of necrotic 
lesions predict the increased chance of recurrence [3, 21]. 
However, in anaplastic meningiomas these features are 
associated with less favourable outcome [26]. Consistent 
with this, recurrence-free survival and median time to 
recurrence were also significantly longer in atypical as 
compared with anaplastic meningiomas. Nevertheless, 
recurrence is not only a features of higher grade (II and 
III) meningiomas, because it also occurs in benign (grade 
I) meningiomas, although less frequently. A study focus-
ing on grade I tumours demonstrated that the chance of 
recurrence is higher in benign meningiomas that have 
small atypical areas within the neoplasm [27]. Overall, 
the most important prognostic factor regarding tumour 
recurrence by far is the histological grade. In WHO grade 
I tumours the chance of recurrence is 7%–25%, in grade II 
29%–59%, whereas in grade III, it is 60%–94% [27].
2.5.2  Immunohistochemical markers 
In immunohistochemical studies the two most frequently 
examined proteins are Ki-67 and p53; their role in tumour 
recurrence has been extensively studied. p53 is a tran-
scription factor with an important role in regulation of 
cell cycle, preservation of genomic integrity, induction of 
apoptosis, and inhibition of angiogenesis [28]. p53 is acti-
vated by a wide range of cell-damaging insults, such as 
oxidative stress, hypoglycaemia, hypoxia, DNA damage, 
oncogene expression, ribosomal dysfunction, and telo-
mere damage [29]. p53 is one of the most important tumour 
suppressor proteins: more than 50% of tumours harbour 
Table 1: WHO classification of meningiomas (modified from Perry et al. [2] )
WHO grade I. meningothelial
microcystic
fibroblastic
secretory
transitional
lymphoplasmacyte-rich
psammomatous
metaplastic
angiomatous
clear cell (spinal)
WHO grade II. chordoid clear cell 
(intracranial)
atypical
WHO grade III. papillary rhabdoid anaplastic
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p53 mutation [15, 16]. Despite the large number of studies, 
the role of p53 in meningioma development and recur-
rence remains unclear. Some authors describe significant 
correlation between p53 immunoreactivity and recurrence 
[30, 31], whereas other studies could not confirm that cor-
relation [6].
The Ki-67 protein is expressed in mitotic cells. In the 
routine pathological diagnostics, the protein is detected 
by the Mib-1 antibody clone. Ki-67 is detectable in all 
phases of the active cell cycle; however, it is missing in 
G0. Furthermore, it plays a role in ribosomal-RNA synthe-
sis [32]. The amount of the protein is closely correlated 
with the proliferative activity of the cell: in the interphase 
it is localized in the nucleoli, whereas in the mitotic phase 
it is on the surface of chromosomes. Therefore, the Ki67 
protein is an excellent marker for detection of the prolifer-
ative pool of a given cell population [33]. Numerous studies 
have demonstrated a significant correlation between an 
increased Ki-67 (Mib-1) labelling index and recurrence [31, 
34-35]. The Ki-67 labelling index also increases with WHO 
grade in meningiomas. Interestingly, in recurring WHO 
grade I tumours, a higher Ki-67 labelling index is present 
[31]. There is also a significant correlation between extent 
of peritumoral oedema and expression of the marker [36].
In addition to the markers mentioned previously, 
there are other important proteins that are recognised in 
meningiomas. The epithelial membrane antigen (EMA) 
and the progesterone receptor (PR) are diagnostic markers 
frequently found in these tumours [37, 38].
Immunohistochemical and other molecular studies 
have rendered electron microscopic analysis less rele-
vant and less important in meningiomas than previously; 
however, in rare and unusual cases, electron microscopy 
may be a useful contributor to diagnosis [39]. Molecular 
and genetic studies establish novel fields of research of 
meningioma pathogenesis. Immunohistochemistry is 
considered to be a standard and well established tool to 
test and analyse novel proteins implicated in tumorigen-
esis. Therefore, it remains an important research method. 
The tissue microarray (TMA) technique enables cheap and 
rapid assessment of candidate proteins in large numbers 
of tumour samples [40]. A recent article raises the possi-
bility that poly(ADP-ribose) polymerase-1 (PARP1), which 
is an enzyme involved in DNA repair, may have prognostic 
implications in meningioma [41].
2.6  Neurosurgical aspects
In meningiomas with clinical symptoms, surgical resec-
tion is the primary choice for treatment in the majority of 
the cases. The aim of the surgical procedure is the com-
plete resection of tumour (if possible) to achieve the best 
quality of life for the patient and to reduce the risk of 
recurrence. The extent of resection is graded according to 
Simpson, using a 5-tier scale [24]. There is close correla-
tion between Simpson grade and risk of recurrence [3]. 
In higher Simpson grades (III-V) disease-free survival is 
shorter, quality of life is reduced, and there is an increased 
chance of early recurrence of the tumour [5, 22, 41, 42] 
(Table 2). Rarely, ‘seeding metastasis’ may occur along 
the surgical tract in deep-seated meningiomas with risk 
of recurrence [43].
In cranial base meningiomas, surgical removal often 
presents a higher risk for postoperative complications. In 
such situations, stereotactic radiosurgery can be successful 
Table 2: Simpson grading system for removal of meningiomas (modified from www.radiopaedia.org [40])
Extent of macroscopic resection Removal of dural tail Risk of recurrence(10 year interval)
Grade I Macroscopically complete(tumour, involved bones and venous sinuses) Macroscopically complete 9%
Grade II Macroscopically complete (tumour) Coagulation 19%
Grade III Macroscopically complete (tumour) No resection 29%
Grade IV Partial removal No resection 44%
Grade V Simple decompression with or without biopsy No resection 100%
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for tumor control. The main indications for both treatment 
methods (i.e., surgery and radiosurgery) are the possibility 
of radiological or neurological progression. However, in a 
great proportion of cranial base meningiomas – especially 
in the elderly – follow-up proves no progression; in this 
case in symptomless patients, a neurosurgical procedure 
or radiosurgery is not evidently necessary. On the other 
hand, increasing tumor size can increase the risk of repeat 
surgical removal or irradiation. Thus, one main chal-
lenge for clinicians is to determine factors that correlate 
with tumor progression in grade I meningiomas. For this 
reason, some studies have already been published: one 
such investigates ornithine decarboxylase (ODC) activity 
and mRNA expression in meningiomas [44]. That report 
describes a significant correlation between ODC mRNA 
level in meningiomas with later recurrence and meningi-
omas without recurrence, despite the same Ki-67 prolifer-
ative index in both populations. These findings suggest a 
role of ODC gene expression in meningiomas recurrence.
3  Conclusion
Although meningiomas are tumours that occur with high 
frequency, the mechanisms underlying pathogenesis, 
recurrence, and progression remain poorly understood. 
With recent advances in diagnostics, treatments, and 
research methods, there is high hope for reduced recur-
rence and more efficient treatment. This requires a mul-
tidisciplinary approach and will have a major impact on 
more effective, personalised therapies, and overall, a 
better clinical outcome for meningioma patients.
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